← Back to headlines
J&J gains monthly dosing approval for Rybrevant Faspro
Johnson & Johnson has secured approval for monthly dosing of its drug Rybrevant Faspro, offering a new treatment option.
17 Feb, 14:18 — 17 Feb, 14:18
Sources
Showing 1 of 1 sources
